Restart Life Sciences Corp. is a Canada-based life sciences company. The Company is focused on delivering wellness solutions that address health and lifestyle challenges. The Company is developing a portfolio of health-focused products, with a focus on brain health, cognitive function, and memory enhancement. The Company is focused on developing natural remedies specifically tailored for individuals on the autism spectrum. It offers BrainQ Cereal, which is crafted with a blend of whole grains, superfoods, and essential nutrients. It also offers Brain Balls, which is a functional snack designed to support cognitive performance, focus, and mental clarity. It owns Holy Crap Foods, which is a cereal brand made from organic seeds like chia, buckwheat, and hemp. Holy Crap is a gluten-free, plant-based, and non-genetically modified organism; its nutrient-dense blends support digestive health, balanced energy, and overall wellness.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
06/08/26	US$0.0697	+7.23%	700
05/08/26	US$0.0650	-27.78%	1,945
03/08/26	US$0.0900	+41.96%	18,736

Delayed Quote OTC Markets

More quotes

Income Statement and Estimates

More financial data

Market Closed - OTC Markets Other stock markets 20:19:58 06/08/2026 BST			5-day change	1st Jan Change
0.0697 ^USD	+7.23%		+9.94%	-19.40%

07-21	Restart Life Sciences Launches Updated AI-Driven E-Commerce Platform and Expands Holy Crap Foods Product Line	CI
07-14	Restart Life Sciences Corp. And University Of Manitoba Richardson Centre For Food Technology And Research Collaborate For Pre-Production Transition Of New Protein Frameworks	CI

Market Cap	4.36M 3.13M 2.71M 2.53M 2.32M 298M 4.43M 29.68M 11.65M 149M 11.76M 11.5M 494M	P/E 2024	6x	P/E 2025	-3.05x
Enterprise Value	2.96M 2.12M 1.84M 1.71M 1.57M 202M 3M 20.11M 7.89M 101M 7.97M 7.79M 335M	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	93.45%	Yield 2024 *	-	Yield 2025	-

07-21	Restart Life Sciences Launches Updated AI-Driven E-Commerce Platform and Expands Holy Crap Foods Product Line	CI
07-14	Restart Life Sciences Corp. And University Of Manitoba Richardson Centre For Food Technology And Research Collaborate For Pre-Production Transition Of New Protein Frameworks	CI
06-04	Restart Life Sciences Corp. Announces Chief Financial Officer Changes, Effective 04 June 2026	CI
06-03	Restart Life Sciences Appoints Inez Ho as Chief Financial Officer	MT
05-26	Restart Life Sciences Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-20	Restart Life Sciences Corp. announced that it has received CAD 0.1 million in funding	CI
05-15	Restart Life Sciences Corp. Advances New Product Relaunch Utilizing Acquired Intellectual Property Portfolio	CI
05-07	Restart Life Sciences Corp Appoints Lindsay Hamelin as Independent Director, Effective 08 May 2026	CI
05-07	Holy Crap Foods Inc. announced that it expects to receive CAD 0.1 million in funding from Restart Life Sciences Corp.	CI
05-07	Restart Life Sciences Corp. announced that it expects to receive CAD 0.1 million in funding	CI
04-30	Restart Life Sciences Corp and University of Manitoba Richardson Centre for Food Technology and Research Extend Research Collaboration	CI
04-25	Restart Life Sciences Corp. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-23	Restart Life Sciences Corp. Auditor Raises 'Going Concern' Doubt	CI

07-29	Restart Life Sciences Announces Strategic Focus on Targeted M&A Expansion in Health and CPG Sectors	NE
07-21	Restart Life Sciences Details U.S. E-Commerce Launch, AI Platform, and Three-Phase Expansion Strategy for Holy Crap Foods	NE
07-14	Restart Life Sciences Leverages University of Manitoba RCFTR Collaboration for Pre-Production Transition of New Protein Frameworks	NE
07-08	Restart Life Sciences Details Next-Generation Product Pipeline and Segment Expansion for Holy Crap	NE
07-02	Restart Life Sciences Reports Record-Breaking June Revenue for Holy Crap Foods as Amazon Canada Sales Surge YoY	NE

Restart Life Sciences Corp. Share Price OTC Markets

Stocks

NMLSF

CA76134J2065

Biotechnology & Medical Research

Valuation: Restart Life Sciences Corp.

Chart: Restart Life Sciences Corp.

Latest news : Restart Life Sciences Corp.

Press Releases: Restart Life Sciences Corp.

News in other languages: Restart Life Sciences Corp.

Quotes and Performance

Course Extremes

Managers and Directors: Restart Life Sciences Corp.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

16/06/22	Nova Mentis dépose un brevet portant sur le diagnostic, la surveillance et le traitement des maladies neurologiques à l'aide de dérivés psychoactifs de la tryptamine
09/06/22	Nova Mentis et la University of Central Florida vont développer un test permettant de mesurer la sérotonine dans la salive
07/06/22	Nova Mentis reçoit une autorisation d'exportation de substances contrôlées de la part du DEA américain pour son médicament exclusif à base de psilocybine le NM 1001
12/05/22	Nova Mentis accueille un analyste du comportement autistique dans son équipe scientifique
03/03/21	Nova Mentis Life Science: Nova Mentis beginnt mit Autismus-Mikrobiom-Studie in den Vereinigten Staaten

1 day	+7.23%
1 week	+9.94%
Current month	+9.94%
1 month	+99.14%
3 months	-6.32%
6 months	-15.21%
Current year	-19.40%

1 week	0.01	0.09
1 month	0.01	0.09
Current year	0.01	0.12
1 year	0.01	0.12
3 years	0.01	0.28
5 years	0.01	1.26
10 years	0.01	32.3

Manager	Title	Age	Since
Steve Loutskou CEO	Chief Executive Officer	-	21/10/2024
Inez Ho DFI	Director of Finance/CFO	42	02/06/2026
Kelly Pladson ADM	Chief Administrative Officer	44	31/01/2017

Director	Title	Age	Since
Georg Hochwimmer BRD	Director/Board Member	58	02/01/2024
Steve Loutskou CHM	Chairman	-	21/10/2024
Khavita Harrycharran BRD	Director/Board Member	-	09/12/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RESTART LIFE SCIENCES CORP.	+7.23%	+9.94%	-	-	3.13M
LONZA GROUP AG	+0.99%	+1.78%	+4.07%	+16.73%	49.47B
REVOLUTION MEDICINES, INC.	+3.71%	+9.40%	+486.98%	+592.14%	43.61B
BEONE MEDICINES AG	+5.60%	+10.21%	+16.76%	+85.72%	39.6B
IQVIA HOLDINGS INC.	+2.70%	+1.57%	+33.39%	+8.85%	39.29B
CELLTRION, INC.	+2.21%	+6.75%	+21.31%	+53.37%	32.43B
ASCENDIS PHARMA A/S	+2.23%	+4.71%	-	-	16.84B
MEDPACE HOLDINGS, INC.	+0.97%	+2.35%	+37.75%	+126.84%	16.49B
EUROFINS SCIENTIFIC SE	-0.11%	+2.41%	+6.24%	+18.87%	14.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.75%	+15.04%	+78.59%	+30.30%	12.77B
Average	+2.63%	+6.32%	+85.64%	+116.60%	29.39B
Weighted average by Cap.	+2.54%	+6.10%	+104.25%	+140.79%

	2024	2025
Net sales	-	-
Net income	225K 161K 139K 130K 119K 15.35M 228K 1.53M 600K 7.69M 606K 592K 25.43M	-1.39M -998K -863K -806K -739K -94.95M -1.41M -9.46M -3.71M -47.59M -3.75M -3.66M -157M
Net Debt	-86.02K -61.72K -53.39K -49.86K -45.74K -5.87M -87.39K -585K -230K -2.94M -232K -227K -9.73M	-1.41M -1.01M -873K -816K -748K -96.09M -1.43M -9.57M -3.76M -48.16M -3.79M -3.71M -159M